NASDAQ · CYCC
Healthcare · Biotechnology
$6.37
Down-$0.41 (-5.98%)
Updated Sep 17, 2026, 9:22 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CYCC does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CYCC.
CYCC research
Company profile and research snapshot.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 3, 2024 | Roth MKM | Buy | — |
| Dec 19, 2023 | Brookline Capital | Hold | — |
| Dec 19, 2023 | Roth MKM | Buy | — |
| May 25, 2023 | Oppenheimer | Outperform | — |
| Mar 7, 2023 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 4, 2025
Cyclacel Pharmaceuticals reported preclinical study findings demonstrating that biliary tract cancer cells are sensitive to plogosertib, a PLK1 inhibitor, with potential for targeted cancer treatment using BUBR1 as a biomarker.
GlobeNewswire Inc. · Jul 7, 2025
Cyclacel Pharmaceuticals has amended an exchange agreement with FITTERS Diversified Berhad to acquire all ordinary shares of Fitters Sdn. Bhd., issuing 19.99% of its stock and paying $1 million, with the transaction subject to stockholder approvals.
GlobeNewswire Inc. · Jul 7, 2025
Cyclacel Pharmaceuticals published research showing its drug plogosertib could potentially treat fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer with no current approved treatments, primarily affecting adolescents and young adults.
GlobeNewswire Inc. · May 15, 2025
Cyclacel Pharmaceuticals announced its Q1 2025 financial results, including a focus on the development of plogosertib and the deconsolidation of its UK subsidiary Cyclacel Limited. The company is exploring strategic alternatives to continue as a going concern, including a share exchange agreement with FITTERS Diversified Berhad.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CYCC.
No results
No recent SID articles mention CYCC.
